Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Xellia Pharmaceuticals
Xellia Pharmaceuticals
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Xellia Cleveland manufacturing facility operational for anti-infectives
In addition to commencing commercial supply, the facility is also preparing ramp-up of its recently installed aseptic bag manufacturing line
Ingredients
Xellia Pharmaceuticals launches additional Vanco Ready doses
Vanco Ready will now cover relevant doses from 500 mg to 2 g in 250 mg increments
Regulatory
Xellia Pharmaceuticals expands approved doses of VANCO READYTM
The drug is universally recognised as a key intervention in the management of sepsi at life-threatening state, as well as other infections
Recruitment
Career Opportunities: Automation Engineer (7243)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Global Packaging Manager, Sterile Products (5677)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Senior Logistics and Process Engineer (6982)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Recruitment
Career Opportunities: Sr Scientist, On Market Products (5942)
Xellia Pharmaceuticals is owned by Novo Holding A/S and is a specialty pharmaceutical company leading in the development, manufacture and supply of anti-infective treatments
Subscribe now